Rituxan and Hepatitis B

A couple weeks ago, US regulators posted a letter stating Rituxan, a Non-Hodgkin's Lymphoma monoclonal antibody treatment, can reactivate hepatitis B virus in patients who have already had the disease.

The US Food and Drug Administration (FDA) has posted new information highlighting this risk. It is said some patients had suffered liver failure or died after rituxan administration.

Patients at high risk of hepatitis B infection should be closely monitored for signs of the disease during and for several months following Rituxan therapy, the agency said.

LymphomaInfo Social